Recovery & Repair · Compounded 503A · Subcutaneous
TB-500: the actin-binding peptide built for tissue repair.
TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide that binds and recruits G-actin — the building block of the cytoskeleton. It is one of the most studied peptides for wound healing, tendon and ligament repair, and tissue flexibility. Frequently paired with BPC-157 for synergistic repair protocols.
Free shipping over $150 · Pay with card or crypto
What TB-500 (Thymosin Beta-4) is
TB-500 is a synthetic version of an active region of Thymosin Beta-4 (Tβ4) — a 43-amino-acid peptide found in nearly every cell in the body. Tβ4 was first isolated from the thymus in 1981 by Allan Goldstein (the same group that characterized Thymosin Alpha-1).
Tβ4 binds G-actin (globular actin) — the monomeric form of the cytoskeleton's main protein. Through this binding, it regulates cytoskeletal dynamics, cell migration, angiogenesis, and the recruitment of stem and progenitor cells to sites of injury.
TB-500 is not FDA-approved. It is compounded by licensed 503A pharmacies and prescribed off-label as a tissue-repair adjunct. It is widely used in equine veterinary medicine for tendon and ligament repair — the equine literature is where much of the original animal evidence comes from.
How it works
TB-500's mechanism is structural — it sequesters G-actin, which both supplies actin to migrating cells and regulates the cytoskeletal rearrangement needed for cell movement. This is the basis for its pro-migratory and pro-healing effects.
Downstream, TB-500 promotes angiogenesis (new blood vessel formation), recruits endothelial progenitor cells, and upregulates expression of laminin-5, integrins, and other repair-associated molecules. The result is faster, more organized tissue repair.
TB-500 also reduces inflammation in injured tissue and decreases scar/fibrosis formation in some models. The combined effect — better cell migration, better vasculature, less fibrosis — is the rationale for its use in tendon, ligament, muscle, and skin injury.
What patients use it for
Tendon and ligament repair
The strongest signal across both animal and clinical experience. TB-500 is widely used as an adjunct in slow-healing tendon injuries (Achilles, rotator cuff, patellar) and ligament injuries.
Wound healing
Tβ4 has been studied in topical formulations for venous stasis ulcers and dry eye (RegeneRx clinical program). Subcutaneous TB-500 is used systemically for similar repair effects.
Flexibility
Patients commonly report improved range of motion and reduced stiffness within 3–6 weeks — consistent with the peptide's effects on cytoskeletal organization and fibrosis reduction.
Pairs well with BPC-157
BPC-157 and TB-500 act through different mechanisms (BPC-157: angiogenesis + NO pathway; TB-500: actin + cell migration). The combination is the most common 'recovery stack' in clinical use.
Evidence summary
The Tβ4 literature is substantial. Crockford D et al. (Annals NY Academy of Sciences, 2010) reviewed safety and efficacy data through Phase 2 in chronic wounds, dry eye, and epidermolysis bullosa — all with acceptable safety.
Goldstein AL et al. (Expert Opinion on Biological Therapy, 2012) reviewed Tβ4 in tissue protection, repair, and regeneration. Animal evidence in cardiac, neural, and corneal repair is broad.
Direct large RCT evidence for off-label TB-500 use in healthy adults with sports injuries is limited. The mechanism, animal data, and clinical experience are strong; honest clinical framing requires acknowledging the gap in head-to-head human trials at sports-medicine doses.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Typical loading protocols use 2–5 mg subcutaneously, 2 times per week for 4–6 weeks, followed by a maintenance phase of 2–5 mg weekly for 4–8 weeks.
Often dosed alongside BPC-157 (250–500 mcg twice daily). The combination protocol is the most common pattern in clinical practice for orthopedic and connective-tissue injury.
Injection site is generally subcutaneous abdomen or near the injury when appropriate. Course length is individualized to injury type and response.
Safety and contraindications
Well-tolerated in clinical experience. Most common side effect is mild injection-site reaction. Some patients report transient malaise or head pressure with the first few doses.
Contraindications: pregnancy, active malignancy (Tβ4's effects on angiogenesis and cell migration are not desirable in active cancer). Discuss any history of cancer with your physician.
Compounded TB-500 in the U.S. is not FDA-approved. Off-label use under physician supervision through a licensed 503A pharmacy.
Who it's typically considered for
- Adults with slow-healing tendon or ligament injuries (with appropriate orthopedic evaluation)
- Patients in post-surgical rehab where additional tissue-repair support is warranted
- Athletes with chronic overuse injuries — in coordination with a sports medicine physician
- Patients already on or considering BPC-157 (the two are commonly paired)
Frequently asked questions
Is TB-500 the same as Thymosin Beta-4?
TB-500 is a synthetic version of an active region of Thymosin Beta-4. In practical clinical usage the two terms are often used interchangeably, though strictly speaking Tβ4 is the full 43-amino-acid peptide and TB-500 refers to the active fragment.
Is TB-500 banned in sports?
Yes. The World Anti-Doping Agency (WADA) prohibits TB-500 in athletic competition. Competitive athletes subject to drug testing should not use TB-500 without consulting their governing body. This is a sport-specific issue, not a safety issue.
Is TB-500 FDA-approved?
No. TB-500 is not FDA-approved for any indication. Compounded TB-500 is prepared by licensed 503A pharmacies under physician prescription for off-label use.
How long does it take to heal an injury with TB-500?
Most clinical protocols run 6–12 weeks for orthopedic injuries. Patients commonly report progress within 3–4 weeks, with continued improvement over the full course. TB-500 supports — it does not replace — appropriate physical therapy and load management.
Why is TB-500 paired with BPC-157?
They act through different and complementary mechanisms. BPC-157 promotes angiogenesis through the nitric oxide pathway; TB-500 promotes cell migration through actin binding. In clinical practice the combination consistently outperforms either peptide alone for orthopedic indications.
Can women use TB-500?
Yes. There is no sex-specific contraindication. Many women in perimenopause/menopause use TB-500 for orthopedic recovery, where age-related collagen decline can slow normal healing.
Is TB-500 safe in cancer survivors?
TB-500's effects on angiogenesis and cell migration are mechanistically concerning in active cancer. In cancer survivors with no active disease, use should be discussed with both the prescribing physician and the patient's oncologist.
Sources
- Crockford D et al. Thymosin beta 4 — Phase 2 development for dry eye, dermal wounds, and EB. Annals of the NY Academy of Sciences (2010). — pubmed.ncbi.nlm.nih.gov/20840602
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy (2012). — pubmed.ncbi.nlm.nih.gov/22188044
- Sosne G et al. Thymosin beta 4 and the eye: I can see clearly now the pain is gone. Annals of the NY Academy of Sciences (2010). — pubmed.ncbi.nlm.nih.gov/20840603
- Bock-Marquette I et al. Thymosin beta 4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature (2004). — www.nature.com/articles/nature03000
Considering TB-500 (Thymosin Beta-4)?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.